Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xiangyi Jiang

Showing results (1-10 of 45) with videos related to

Pageof 5
Sort By:
Expert Opinion on Drug Discovery|August 30, 2025
Advances in click chemistry for drug discovery and developmentJiaojiao Dai, Xiaojia Xue, Xiangyi Jiang, et al.
Expert Opinion on Drug Discovery|May 17, 2019
Recent applications of click chemistry in drug discoveryXiangyi Jiang, Xia Hao, Lanlan Jing, et al.
Drug Discovery Today|July 1, 2024
Recent advances in the molecular design and applications of viral RNA-targeting antiviral modalitiesJiaojiao Dai, Xiangyi Jiang, Edeildo Ferreira da Silva-Júnior, et al.
Expert Opinion on Drug Discovery|December 8, 2022
The discovery and design of novel HIV-1 capsid modulators and future perspectivesDang Ding, Shujing Xu, Xujie Zhang, et al.
Expert Opinion on Drug Discovery|November 21, 2023
Advances in drug structure-activity-relationships for the development of selenium-based compounds against HIVDazhou Shi, Shujing Xu, Dang Ding, et al.
Journal of Medicinal Chemistry|January 8, 2026
First-in-Class Quinoline-Dione-Derived PROTACs: Potent Degraders of Cdc25 Phosphatases for Antitumor TherapyGuanyu Dong, Mengfei Chen, Xiangyi Jiang, et al.
European Journal of Medicinal Chemistry|November 13, 2024
Discovery of novel fused-heterocycle-bearing diarypyrimidine derivatives as HIV-1 potent NNRTIs targeting tolerant region I for enhanced antiviral activity and resistance profileJiaojiao Dai, Xiangyi Jiang, Heng Gao, et al.
Journal of Medicinal Chemistry|October 20, 2025
Structure- and Privileged Fragment-Based Iterative Optimization: Discovery of 2,4-Disubstituted-6-aminopyrimidines as Novel HIV-1 NNRTIs with Potent Activity against Drug-Resistant Strains and Favorable Safety ProfilesXiangkai Ji, Xiangyi Jiang, Heng Gao, et al.
Journal of Medicinal Chemistry|August 25, 2021
Discovery of Novel Dihydrothiopyrano[4,3-<i>d</i>]pyrimidine Derivatives as Potent HIV-1 NNRTIs with Significantly Reduced hERG Inhibitory Activity and Improved Resistance ProfilesZhao Wang, Waleed A Zalloum, Wenbo Wang, et al.
European Journal of Medicinal Chemistry|September 25, 2020
Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubilityZhao Wang, Dongwei Kang, Da Feng, et al.
Pageof 5

Showing results (1-10 of 45) with videos related to

Sort By:
Pageof 5
Expert Opinion on Drug Discovery|August 30, 2025
Advances in click chemistry for drug discovery and developmentJiaojiao Dai, Xiaojia Xue, Xiangyi Jiang, et al.
Expert Opinion on Drug Discovery|May 17, 2019
Recent applications of click chemistry in drug discoveryXiangyi Jiang, Xia Hao, Lanlan Jing, et al.
Drug Discovery Today|July 1, 2024
Recent advances in the molecular design and applications of viral RNA-targeting antiviral modalitiesJiaojiao Dai, Xiangyi Jiang, Edeildo Ferreira da Silva-Júnior, et al.
Expert Opinion on Drug Discovery|December 8, 2022
The discovery and design of novel HIV-1 capsid modulators and future perspectivesDang Ding, Shujing Xu, Xujie Zhang, et al.
Expert Opinion on Drug Discovery|November 21, 2023
Advances in drug structure-activity-relationships for the development of selenium-based compounds against HIVDazhou Shi, Shujing Xu, Dang Ding, et al.
Journal of Medicinal Chemistry|January 8, 2026
First-in-Class Quinoline-Dione-Derived PROTACs: Potent Degraders of Cdc25 Phosphatases for Antitumor TherapyGuanyu Dong, Mengfei Chen, Xiangyi Jiang, et al.
European Journal of Medicinal Chemistry|November 13, 2024
Discovery of novel fused-heterocycle-bearing diarypyrimidine derivatives as HIV-1 potent NNRTIs targeting tolerant region I for enhanced antiviral activity and resistance profileJiaojiao Dai, Xiangyi Jiang, Heng Gao, et al.
Journal of Medicinal Chemistry|October 20, 2025
Structure- and Privileged Fragment-Based Iterative Optimization: Discovery of 2,4-Disubstituted-6-aminopyrimidines as Novel HIV-1 NNRTIs with Potent Activity against Drug-Resistant Strains and Favorable Safety ProfilesXiangkai Ji, Xiangyi Jiang, Heng Gao, et al.
Journal of Medicinal Chemistry|August 25, 2021
Discovery of Novel Dihydrothiopyrano[4,3-<i>d</i>]pyrimidine Derivatives as Potent HIV-1 NNRTIs with Significantly Reduced hERG Inhibitory Activity and Improved Resistance ProfilesZhao Wang, Waleed A Zalloum, Wenbo Wang, et al.
European Journal of Medicinal Chemistry|September 25, 2020
Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubilityZhao Wang, Dongwei Kang, Da Feng, et al.
Pageof 5